Anforderungen des klinisch tätigen Kardiologen an die nuklearkardiologische Diagnostik

Zusammenfassung

Die Nuklearkardiologie in Deutschland steht derzeit an einem für ihre weitere Entwicklung wichtigen Punkt. Es gilt, die nachgewiesenen und unbestrittenen Stärken z. B. in der Diagnostik der KHK, der Prognoseabschätzung, der Vitalitätsdiagnostik und Fragen der ökonomischen Ressourcennutzung in den Vordergrund zu stellen und die Wertigkeit nuklearmedizinischer Verfahren in diesem Kontext der klinischen Öffentlichkeit besser bekannt zu machen. Im Gegensatz z. B. zu den angelsächsischen Ländern werden in Deutschland weniger Myokardszintigraphien als Koronarangiographien durchgeführt. Das bessere „Marketing” der Nuklearkardiologie, aber auch dem besseren „Service” für die klinisch tätigen Allgemeinärzte, Internisten und Kardiologen/innen in Form von kürzeren Wartezeiten, überweisergerechten Befundberichten sowie vermehrter interdisziplinärer Kommunikation kommt in naher Zukunft ein große Bedeutung zu, um die Nuklearkardiologie nicht durch neue Methoden in den Hintergrund drängen zu lassen.

Abstract

Nuclear Cardiology in Germany is right now at an important step for its future development. It is necessary to increase the publicity to the clinical community with regard to the well known and appreciated strengths of nuclear cardiology. Diagnosis of coronary artery disease (CAD), assessment of prognosis in patients with CAD with or without a history of myocardial infarction, imaging of myocardial viability as well as economic aspects of diagnostic and therapeutic strategies have been validated in numerous studies involving thousands of patients. Clinical “Marketing” of these important aspects has to be significantly improved in the near future. The “service” to the clinical partners, such as general practitioners, internists or cardiologists, needs further improvement as well as interdisciplinary communication to avoid that nuclear cardiology will be replaced by other techniques such as MRI oder MSCT and to assure that nuclear cardiology will play an important role within the clinical work-up of patients with CAD as it has in countries like the US.

Myokardperfusionsszintigraphie - koronare Herzkrankheit - akutes Koronarsyndrom - Kosteneffizienz - klinische Kardiologie

Myocardial perfusion scintigraphy - coronary artery disease - acute coronary syndrome - cost-effectiveness - clinical cardiology

Literatur

• 1 Zaret B L, Wackers F J. Nuclear cardiology (1).  N Engl J Med. 1993;  329 775-783
• 2 Zaret B L, Wackers F J. Nuclear cardiology (2).  N Engl J Med. 1993;  329 855-863
• 3 National Institute of Clinical Excellence .Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction. Technology Appraisal 73. National Institute for Clinical Excellence, London 2003. www.nice.org.uk
• 4 Kapur A, Latus K A, Davies G, Dhawan R T, Eastick S, Jarritt P H, Roussakis G, Young M C, Anagnostopoulos C, Bomanji J, Costa D C, Pennell D J, Prvulovich E M, Ell P J, Underwood S R. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study.  Eur J Nucl Med Mol Imaging. 2002;  29 1608-1616
• 5 Smanio P E, Watson D D, Segalla D L, Vinson E L, Smith W H, Beller G A. Value of gating of technetium-99m sestamibi single-photon emission computed tomographic imaging.  J Am Coll Cardiol. 1997;  30 1687-1692
• 6 Heller G V, Links J, Bateman T M, Ziffer J A, Ficaro E, Cohen M C, Hendel R C. American Society of Nuclear Cardiology and Society of Nuclear Medicine joint position statement: Attenuation correction of myocardial perfusion SPECT scintigraphy.  J Nucl Cardiol. 2004;  11 229
• 7 Hendel R C, Corbett J R, Cullom S J, DePuey E G, Garcia E V, Bateman T M. The value and practice of attenuation correction for myocardial perfusion SPECT imaging: a joint position statement from the American Society of Nuclear Cardiology and the Society of Nuclear Medicine.  J Nucl Cardiol. 2002;  9 135-143
• 8 Beller G A, Zaret B L. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease.  Circulation. 2000;  101 1465-1478
• 9 Schaefers M. Methods and clinical applications in nuclear cardiology: a position statement.  Nuklearmedizin. 2002;  41 3-13
• 10 Underwood S R, Anagnostopoulos C, Cerqueira M, Ell P J, Flint E J, Harbinson M, Kelion A D, Al-Mohammad A, Prvulovich E M, Shaw L J, Tweddel A C. Myocardial perfusion scintigraphy: the evidence. A consensus conference organised by the British Cardiac Society, the British Nuclear Cardiology Society and the British Nuclear Medicine Society, endorsed by the Royal College of Physicians of London and the Royal College of Radiologists.  Eur J Nucl Med Mol Imaging. 2004;  31 261-291
• 11 Hachamovitch R, Berman D S, Kiat H, Bairey C N, Cohen I, Cabico A, Friedman J, Germano G, Van Train K F, Diamond G A. Effective risk stratification using exercise myocardial perfusion SPECT in women: gender-related differences in prognostic nuclear testing.  J Am Coll Cardiol. 1996;  28 34-44
• 12 Shaw L J, Hachamovitch R, Redberg R F. Current evidence on diagnostic testing in women with suspected coronary artery disease: choosing the appropriate test.  Cardiol Rev. 2000;  8 65-74
• 13 Wackers F J, Zaret B L. Detection of myocardial ischemia in patients with diabetes mellitus.  Circulation. 2002;  105 5-7
• 14 Wackers F J. Can acute rest imaging shorten evaluation in chest pain centers?.  J Nucl Cardiol. 1999;  6 676-678
• 15 Heller G V, Stowers S A, Hendel R C, Herman S D, Daher E, Ahlberg A W, Baron J M, Mendes de Leon C F, Rizzo J A, Wackers F J. Clinical value of acute rest technetium-99m tetrofosmin tomographic myocardial perfusion imaging in patients with acute chest pain and nondiagnostic electrocardiograms.  J Am Coll Cardiol. 1998;  31 1011-1017
• 16 Abbott B G, Abdel-Aziz I, Nagula S, Monico E P, Schriver J A, Wackers F J. Selective use of single-photon emission computed tomography myocardial perfusion imaging in a chest pain center.  Am J Cardiol. 2001;  87 1351-1355
• 17 Udelson J E, Beshansky J R, Ballin D S, Feldman J A, Griffith J L, Handler J, Heller G V, Hendel R C, Pope J H, Ruthazer R, Spiegler E J, Woolard R H, Selker H P. Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial.  Jama. 2002;  288 2693-2700
• 18 Hachamovitch R, Berman D S. New frontiers in risk stratification using stress myocardial perfusion single photon emission computed tomography.  Curr Opin Cardiol. 2003;  18 494-502
• 19 Van de Werf F, Ardissino D, Betriu A, Cokkinos D V, Falk E, Fox K A, Julian D, Lengyel M, Neumann F J, Ruzyllo W, Thygesen C, Underwood S R, Vahanian A, Verheugt F W, Wijns W. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.  Eur Heart J. 2003;  24 28-66
• 20 Shaw L J, Hendel R, Borges-Neto S, Lauer M S, Alazraki N, Burnette J, Krawczynska E, Cerqueira M, Maddahi J. Prognostic value of normal exercise and adenosine ^99mTc-tetrofosmin SPECT imaging: results from the multicenter registry of 4 728 patients.  J Nucl Med. 2003;  44 134-139
• 21 Hachamovitch R, Berman D S, Shaw L J, Kiat H, Cohen I, Cabico J A, Friedman J, Diamond G A. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction.  Circulation. 1998;  97 535-543
• 22 Bax J J, van Eck-Smit B L, van der Wall E E. Assessment of tissue viability: clinical demand and problems.  Eur Heart J. 1998;  19 847-858
• 23 Schinkel A F, Bax J J, Boersma E, Elhendy A, Roelandt J R, Poldermans D. How many patients with ischemic cardiomyopathy exhibit viable myocardium?.  Am J Cardiol. 2001;  88 561-564
• 24 Cleland J G, Pennell D J, Ray S G, Coats A J, Macfarlane P W, Murray G D, Mule J D, Vered Z, Lahiri A. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.  Lancet. 2003;  362 14-21
• 25 Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography.  N Engl J Med. 1986;  314 884-888
• 26 Schwaiger M, Beanlands R, vom Dahl J. Metabolic tissue characterization in the failing heart by positron emission tomography.  Eur Heart J. 1994;  15 (Suppl D) 14-19
• 27 vom Dahl J, Schulz G, Koch K C. Diagnostik der chronischen Myokardischämie: Validität nuklearmedizinischer Verfahren.  Z Kardiol. 1998;  87 (Suppl 2) 92-99
• 28 Bax J J, van der Wall E E. Evaluation of myocardial viability in chronic ischemic cardiomyopathy.  Int J Cardiovasc Imaging. 2003;  19 137-140
• 29 Allman K C, Shaw L J, Hachamovitch R, Udelson J E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis.  J Am Coll Cardiol. 2002;  39 1151-1158
• 30 Schwarz E R, Schaper J, vom Dahl J, Altehoefer C, Grohmann B, Schoendube F, Sheehan F H, Uebis R, Buell U, Messmer B J, Schaper W, Hanrath P. Myocyte degeneration and cell death in hibernating human myocardium.  J Am Coll Cardiol. 1996;  27 1577-1585
• 31 Beanlands R S, Hendry P J, Masters R G, de Kemp R A, Woodend K, Ruddy T D. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging.  Circulation. 1998;  98 1151-1156
• 32 Bax J J, Schinkel A F, Boersma E, Rizzello V, Elhendy A, Maat A, Roelandt J R, van der Wall E E, Poldermans D. Early versus delayed revascularization in patients with ischemic cardiomyopathy and substantial viability: impact on outcome.  Circulation. 2003;  108 (Suppl 1) 1139-1142
• 33 Shaw L J, Hachamovitch R, Heller G V, Marwick T H, Travin M I, Iskandrian A E, Kesler K, Lauer M S, Hendel R, Borges-Neto S, Lewin H C, Berman D S, Miller D. Noninvasive strategies for the estimation of cardiac risk in stable chest pain patients. The Economics of Noninvasive Diagnosis (END) Study Group.  Am J Cardiol. 2000;  86 1-7
• 34 Shaw L J, Miller D D, Berman D S, Hachamovitch R. Clinical and economic outcomes assessment in nuclear cardiology.  Q J Nucl Med. 2000;  44 138-152
• 35 Underwood S R, Godman B, Salyani S, Ogle J R, Ell P J. Economics of myocardial perfusion imaging in Europe - the EMPIRE Study.  Eur Heart J. 1999;  20 157-166
• 36 Desideri A, Fioretti P M, Cortigiani L, Gregori D, Coletta C, Vigna C, Tota F, Rambaldi R, Bax J, Celegon L, Bigi R, Picano E. Cost of strategies after myocardial infarction (COSTAMI): a multicentre, international, randomized trial for cost-effective discharge after uncomplicated myocardial infarction.  Eur Heart J. 2003;  24 1630-1639
• 37 Hendel R C, Wackers F J, Berman D S, Ficaro E, Depuey E G, Klein L, Cerqueira M. American society of nuclear cardiology consensus statement: reporting of radionuclide myocardial perfusion imaging studies.  J Nucl Cardiol. 2003;  10 705-708
• 38 Vermeeren P C. Nuclear cardiology in Europe: nuclear medicine physicians tend to build walls around their skills and thereby limit the growth of the field.  J Nucl Cardiol. 1999;  6 241-244